Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Regeneron Pharmaceuticals, Inc. Revenue & Financial Statements
Regeneron Pharmaceuticals, Inc. reported revenue of $14.3B for the fiscal year ended December 31, 2025, up 1.0% year over year, with net income of $4.5B and diluted EPS of $41.48.
- Company
- Regeneron Pharmaceuticals, Inc. REGN · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 16.1B | 12.2B | 13.1B | 14.2B | 14.3B |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | 8.9B | 4.7B | 4.0B | 4.0B | 3.6B |
| Pretax income | 5.9B | 839.9M | (362.3M) | (411.3M) | 5.7B |
| Net income | 8.1B | 4.3B | 4.0B | 4.4B | 4.5B |
| Diluted EPS | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 |
| EBITDA | 9.2B | 5.1B | 4.5B | 4.5B | 4.1B |
Quarterly
| USD | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.5B | 3.7B | 3.8B | 3.0B | — | 3.7B | 3.8B | 3.9B |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | 1.1B | 1.2B | 990.2M | 591.7M | — | 1.1B | 1.0B | 879.9M |
| Pretax income | 1.6B | 1.5B | 958.1M | 905.0M | — | 1.5B | 1.8B | 1.0B |
| Net income | 1.4B | 1.3B | 917.7M | 808.7M | 1.4B | 1.4B | 1.5B | 844.6M |
| Diluted EPS | 12.41 | 11.54 | 8.11 | 7.27 | — | 12.81 | 13.62 | 7.87 |
| EBITDA | — | 1.3B | 1.1B | 718.6M | — | — | 1.2B | 1.0B |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 25.4B | 29.2B | 33.1B | 37.8B | 40.6B |
| Current assets | 14.0B | 15.9B | 19.5B | 18.7B | 18.0B |
| Cash & equivalents | 2.9B | 3.1B | 2.7B | 2.5B | 3.1B |
| Total liabilities | 6.7B | 6.6B | 7.1B | 8.4B | 9.3B |
| Current liabilities | 3.9B | 3.1B | 3.4B | 3.9B | 4.4B |
| Long-term debt | 2.0B | 2.0B | 2.0B | 2.0B | 2.0B |
| Total debt | 2.0B | 2.0B | 2.0B | 2.0B | 2.0B |
| Stockholders’ equity | 18.8B | 22.7B | 26.0B | 29.4B | 31.3B |
| Net debt | (905.6M) | (1.1B) | (747.1M) | (503.8M) | (1.1B) |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 7.1B | 5.0B | 4.6B | 4.4B | 5.0B |
| Investing cash flow | (5.4B) | (3.8B) | (3.2B) | (2.5B) | (629.1M) |
| Financing cash flow | (1.0B) | (1.0B) | (1.8B) | (2.2B) | (3.7B) |
| Capital expenditure | — | — | — | — | — |
| Free cash flow | — | — | — | — | — |
| Dividends paid | — | — | — | — | 370.3M |
| Stock-based compensation | 601.7M | 725.0M | 885.0M | 982.8M | 993.7M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every REGN filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.